Low Residue Diet Tested as Treatment for Gut Problems in Mitochondrial Disease
A completed trial explores whether a low-fibre diet can ease intestinal dysmotility — one of the most debilitating but overlooked symptoms of mitochondrial disease.
Summary
Intestinal dysmotility, or chronically slow gut movement, is a serious and under-recognised complication of mitochondrial disease affecting both adults and children. Standard treatments like laxatives and motility drugs often fall short. This completed trial from Newcastle University tested whether a low residue diet — restricting fibre to under 10 grams per day — could reduce gut workload and improve symptoms. Researchers examined stool frequency, consistency, abdominal pain, bloating, and constipation, as well as quality of life, gut microbiome composition, physical activity, dietary patterns, and metabolic markers including kidney function, liver function, and lipid profiles. X-ray transit studies were also used to objectively measure gut movement speed. The findings could offer a simple, accessible dietary strategy for a patient population with very limited therapeutic options.
Detailed Summary
Mitochondrial disease is a complex, multi-system condition in which defective energy production in cells leads to widespread organ dysfunction. One increasingly recognised but poorly managed manifestation is intestinal dysmotility — a chronic slowing of gut movement that causes severe abdominal pain, bloating, constipation, and significant reductions in quality of life. Existing pharmacological interventions, including laxatives and prokinetic agents, yield inconsistent results, leaving patients with few reliable options.
This completed clinical trial, sponsored by Newcastle University, investigated whether a low residue diet could serve as a practical dietary intervention for this problem. A low residue diet limits fibre intake to below 10 grams per day, reducing faecal bulk and volume, thereby decreasing colonic workload and promoting bowel rest. While this approach has been validated in other gastrointestinal conditions, its application in mitochondrial disease had never been formally studied.
The study examined a broad range of outcomes: stool frequency and consistency, subjective gut symptom burden, quality of life, dietary tolerance and compliance, physical activity levels, gut microbiome changes, and anthropometric measures such as BMI and waist-to-hip ratio. Notably, radiological transit studies using X-ray were included to objectively confirm slowed gut motility and assess whether the dietary intervention altered transit speed. Blood markers of kidney function, liver function, and lipid profiles were also tracked.
These findings are potentially important because they could validate a low-cost, non-pharmacological dietary strategy for a patient population with severely limited options. If effective, a low residue diet could be implemented rapidly in clinical settings with minimal risk.
However, because only the trial registration abstract is available, no results data can be reported. The full published outcomes remain unknown, limiting interpretation of the trial's impact. The relatively niche patient population may also restrict generalisability to broader gut motility disorders.
Key Findings
- Trial tested whether <10g/day fibre diet reduces stool frequency, pain, and bloating in mitochondrial disease patients.
- X-ray transit studies used to objectively confirm slow gut motility and detect diet-related changes in movement speed.
- Gut microbiome composition was monitored to assess whether low residue diet alters bacterial populations.
- Quality of life, physical activity, and metabolic blood markers tracked as secondary outcome measures.
- Study addresses a major unmet clinical need — standard motility drugs provide only variable relief in this population.
Methodology
This is a completed interventional trial (Phase N/A) registered on ClinicalTrials.gov (NCT03388528), sponsored by Newcastle University. The intervention was a low residue diet restricting fibre to under 10g per day, with outcomes including clinical, radiological, microbiome, and biochemical measures. No control arm or blinding details are available from the abstract alone.
Study Limitations
This summary is based on the trial registration abstract only — no results, outcome data, or statistical findings are available, significantly limiting interpretability. The patient population is highly specialised, and findings may not generalise to other forms of gut dysmotility or chronic disease. Study design details including sample size, blinding, and control conditions are not described in the available abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.